Patents by Inventor Thomas Brimert

Thomas Brimert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Galactoside inhibitor of galectins
    Patent number: 11919921
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: March 5, 2024
    Assignee: GALECTO BIOTECH AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20220289783
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 15, 2022
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 11377464
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: July 5, 2022
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20210380624
    Abstract: A compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 9, 2021
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Thomas BRIMERT, Kristoffer PETERSON, Karl JANSSON
  • 2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS
    Publication number: 20210101913
    Abstract: A compound of formula (I?) wherein R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R7 is as defined for R6; or and R7 taken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g.
    Type: Application
    Filed: October 21, 2020
    Publication date: April 8, 2021
    Inventors: Berit Johansen, Marcel Sandberg, Inger-Reidun Aukrust, George Kokotos, Johan Evenäs, Thomas Brimert, Kildahl-Andersen Geir
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200407391
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • 2-oxothiatole compounds having activity as cPLAinhibitors for the treatment of inflammatory disorders and hyperproliferative disorders
    Patent number: 10851114
    Abstract: A compound of formula (I?) wherein R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R7 is as defined for R6; or and R7 taken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 1, 2020
    Assignee: Avexxin AS
    Inventors: Berit Johansen, Marcel Sandberg, Inger-Reidun Aukrust, George Kokotos, Johan Evenäs, Thomas Brimert, Kildahl-Andersen Geir
  • Galactoside inhibitor of galectins
    Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • 1,1 ?-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins
    Patent number: 10730902
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 4, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Anders Pedersen, Hans Schambye, Thomas Brimert, Richard Johnsson
  • Galactoside inhibitor of galectins
    Patent number: 10526360
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 7, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20190359643
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 28, 2019
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • 2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS
    Publication number: 20190345168
    Abstract: A compound of formula (I?) wherein R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R7 is us defined for R6; or and R7 taken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g.
    Type: Application
    Filed: December 10, 2018
    Publication date: November 14, 2019
    Inventors: Berit Johansen, Marcel Sandberg, Inger-Reidun Aukrust, George Kokotos, Johan Evenäs, Thomas Brimert, Kildahl-Andersen Geir
  • Galactoside inhibitor of galectins
    Patent number: 10464964
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: November 5, 2019
    Assignee: Galecto Biotech AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Thomas Brimert, Richard Johnsson, Priya Verma
  • 2-oxothiatole compounds having activity as CPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders
    Patent number: 10150781
    Abstract: A compound of formula (I?) wherein R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R7 is as defined for R6; or R6 and R7 taken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: December 11, 2018
    Assignee: Avexxin AS
    Inventors: Berit Johansen, Marcel Sanderberg, Inger-Reidun Aukrust, George Kokotos, Johan Evenäs, Thomas Brimert, Kildahl-Andersen Geir
  • NOVEL GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20180327440
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: November 8, 2016
    Publication date: November 15, 2018
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Anders PEDERSEN, Hans SCHAMBYE, Thomas BRIMERT, Richard JOHNSSON
  • Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes
    Patent number: 10011597
    Abstract: Disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: July 3, 2018
    Assignee: APOGLYX AB
    Inventors: Michael Rützler, Thomas Brimert, Klaus Dreisch, Johan Evenäs, Joakim Larsson
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20170349619
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 28, 2016
    Publication date: December 7, 2017
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20170334940
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 14, 2016
    Publication date: November 23, 2017
    Applicant: Galecto Biotech AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Thomas BRIMERT, Richard JOHNSSON, Priya VERMA
  • DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES
    Publication number: 20170320869
    Abstract: Disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 9, 2017
    Inventors: Michael RÜTZLER, Thomas BRIMERT, Klaus DREISCH, Johan EVENÄS, Joakim LARSSON
  • 2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS
    Publication number: 20170166589
    Abstract: A compound of formula (I?) wherein R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R7 is as defined for R6; or R6 and R7 taken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g.
    Type: Application
    Filed: August 3, 2015
    Publication date: June 15, 2017
    Inventors: Berit Johansen, Marcel Sanderberg, Inger-Reidun Aukrust, George Kokotos, Johan Evenäs, Thomas Brimert, Kildahl-Andersen Geir